Afuco™ Anti-Human GLG1 ADCC Therapeutic Antibody (PAT-PA1), ADCC Enhanced
Anti-GLG1 ADCC Enhanced Antibody (PAT-PA1) is an ADCC enhanced antibody produced by our Afuco™ platform. The human antibody PAT-PA1 has already been shown to effectively kill a number of different types of cancer, including significantly reducing gastric and pancreatic tumours in animal models of human cancer, with no adverse side effects.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-302CL |
| Pricing | Inquiry |
| Host | Human |
| Target | GLG1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C. |